Heterologous Biosynthesis of Methanobactin from Methylocystis sp. Strain SB2 in Methylosinus trichosporium OB3b
ACS Synthetic Biology · 16.08.2024 · 13 (8) · 2347-2356
DOI: 10.1021/acssynbio.4c00026 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, online erschienen am 07.08.2024. Verfasst von Peng Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Civil and Environmental Engineering, University of Michigan, Ann Arbor, Michigan 48109-2125, United States. Hauptthemen laut MEDLINE: Methylosinus trichosporium, Imidazoles, Oligopeptides, Methylocystaceae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Office of Science, National Science Foundation.
Abstract (Originalsprache)
Aerobic methanotrophs, or methane-consuming microbes, are strongly dependent on copper for their activity. To satisfy this requirement, some methanotrophs produce a copper-binding compound, or chalkophore, called methanobactin (MB). In addition to playing a critical role in methanotrophy, MB has also been shown to have great promise in treating copper-related human diseases, perhaps most significantly Wilson’s disease. In this congenital disorder, copper builds up in the liver, leading to irreversible damage and, in severe cases, complete organ failure. Remarkably, MB has been shown to reverse such damage in animal models, and there is a great deal of interest in upscaling MB production for expanded clinical trials. Such efforts, however, are currently hampered as (1) the natural rate of MB production rate by methanotrophs is low, (2) the use of methane as a substrate for MB production is problematic as it is explosive in air, (3) there is limited understanding of the entire pathway of MB biosynthesis, and (4) the most attractive form of MB is produced by Methylocystis sp. strain SB2, a methanotroph that is genetically intractable. Herein, we report heterologous biosynthesis of MB from Methylocystis sp. strain SB2 in an alternative methanotroph, Methylosinus trichosporium OB3b, not only on methane but also on methanol. As a result, the strategy described herein not only facilitates enhanced MB production but also provides opportunities to construct various mutants to delineate the entire pathway of MB biosynthesis, as well as the creation of modified forms of MB that may have enhanced therapeutic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Civil and Environmental Engineering, University of Michigan, Ann Arbor, Michigan 48109-2125, United States.
- Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, Iowa 50011-3260, United States.
- Office of Biotechnology Protein Facility, Iowa State University, Ames, Iowa 50011-3260, United States.
ORCID-Profile: Peng Peng, Jeremy D Semrau
Förderung
- Office of Science
- National Science Foundation
Zitieren
APA
Peng, P., DiSpirito, A. A., Lewis, B. J., Nott, J. D., & Semrau, J. D. (2024). Heterologous Biosynthesis of Methanobactin from Methylocystis sp. Strain SB2 in Methylosinus trichosporium OB3b. ACS Synthetic Biology, 13(8), 2347-2356. https://doi.org/10.1021/acssynbio.4c00026
Vancouver
Peng P, DiSpirito AA, Lewis BJ, Nott JD, Semrau JD. Heterologous Biosynthesis of Methanobactin from Methylocystis sp. Strain SB2 in Methylosinus trichosporium OB3b. ACS Synthetic Biology. 2024;13(8):2347-2356. doi:10.1021/acssynbio.4c00026
BibTeX
@article{Peng2024,
author = {Peng, Peng and DiSpirito, Alan A and Lewis, Braden J and Nott, Joel D and Semrau, Jeremy D},
title = {Heterologous Biosynthesis of Methanobactin from Methylocystis sp. Strain SB2 in Methylosinus trichosporium OB3b},
journal = {ACS Synthetic Biology},
year = {2024},
volume = {13},
number = {8},
pages = {2347--2356},
doi = {10.1021/acssynbio.4c00026}
}
EUVIMED